Monday, April 15, 2013
Last week's flurry of IPO news,
including the largest offering since 2011, suggests biotech companies believe
investors are now looking for new stories after pouring money into already
public names during the sector's lengthening bull run.
JMP banker Bob Carey said
several elements are in place to support the opening of an IPO window, the most
important of which is the amount of cash investors are looking to put to work
as the sector continues to outperform.